Last reviewed · How we verify
Radiolabeled autologous seminal fluid
Radiolabeled autologous seminal fluid is a Biologic drug developed by Johns Hopkins University. It is currently in Phase 1 development.
At a glance
| Generic name | Radiolabeled autologous seminal fluid |
|---|---|
| Sponsor | Johns Hopkins University |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effect of Seminal Fluid on the Colon Wall; Implications for HIV Transmission (NA)
- An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Radiolabeled autologous seminal fluid CI brief — competitive landscape report
- Radiolabeled autologous seminal fluid updates RSS · CI watch RSS
- Johns Hopkins University portfolio CI
Frequently asked questions about Radiolabeled autologous seminal fluid
What is Radiolabeled autologous seminal fluid?
Radiolabeled autologous seminal fluid is a Biologic drug developed by Johns Hopkins University.
Who makes Radiolabeled autologous seminal fluid?
Radiolabeled autologous seminal fluid is developed by Johns Hopkins University (see full Johns Hopkins University pipeline at /company/johns-hopkins-university).
What development phase is Radiolabeled autologous seminal fluid in?
Radiolabeled autologous seminal fluid is in Phase 1.